India · Delayed Price · Currency is INR Gufic Biosciences Earnings Call Transcripts
Fiscal Year 2026
-
Q3 FY26 saw flat sequential revenue and margins, with export growth offset by domestic operational changes and debtor corrections. Indore ramp-up and regulatory approvals are set to drive 15%+ growth and margin expansion in FY27, with export revenue from Europe expected to begin in Q3/Q4.
-
Revenue and margins improved sequentially, driven by Indore facility ramp-up and strong international growth. Indore contributed all incremental revenue, with capacity utilization at 23-25%. CMO and domestic segments are set for further growth as more clients transition and new products launch.
-
Revenue grew 10% sequentially to INR 226.96 crore, driven by the Indore facility ramp-up and strong export momentum. EBITDA and profit margins improved, with further gains expected as capacity utilization and exports increase. Indore is set to become a margin accretive asset from FY 2027.
Fiscal Year 2025
-
Revenue and EBITDA grew modestly year-over-year, but margins declined due to higher fixed costs from the new Indoor facility. International and botulinum toxin businesses are set for strong growth, with Indoor expected to reach EBITDA break-even in FY26 and full ramp-up by FY28.
-
Q3 FY25 saw stable revenues and margins, with new product launches in fertility and critical care driving growth. Indore facility began production, with ramp-up and break-even expected over the next year, while margin pressure persists due to expansion costs.
-
Revenue and profit margins remained stable despite a slight YoY decline, as the Indore facility began phased production with minimal FY25 impact. Strategic business units expanded, and international growth was supported by new approvals and a UK NHS tender.
-
Q1 FY25 saw modest revenue and profit growth, with stable margins amid capacity constraints. Indore facility validation is nearly complete, with commercial production set to drive scale, margin expansion, and export growth. Debt is stable, with deleveraging planned as new capacity ramps up.